Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis

Area of Science:

• Rheumatology
• Pharmacology
• Clinical Trials

Background:

• Systemic sclerosis (SSc) frequently causes severe Raynaud's phenomenon (RP).
• Idiopathic RP is typically less severe than SSc-associated RP.
• Efficacy of calcium-channel blockers (CCBs) for SSc-RP requires further investigation.

Purpose of the Study:

• To conduct a meta-analysis evaluating CCBs for treating RP in SSc patients.
• To assess the impact of CCBs on ischemic attack frequency and severity.
• To analyze digital skin temperature, patient/physician global assessments, and digital ulcers.

Main Methods:

• A systematic Cochrane search strategy was employed across multiple databases.
• Included were 8 randomized controlled trials (RCTs) with >2 days duration and <35% dropout rate.
• Data from 109 patients were analyzed, with challenges in extracting SSc-specific data.

Main Results:

• CCBs significantly reduced ischemic attack frequency (WMD -8.31) and severity (SMD -0.69) versus placebo.
• Nifedipine alone also showed significant reductions in attack frequency (WMD -10.21) and severity (SMD -0.99).
• Effect sizes suggest moderate clinical improvement.

Conclusions:

• CCBs demonstrate moderate efficacy in improving both frequency and severity of ischemic attacks in SSc-related RP.
• Potential bias exists due to crossover trial designs lacking order effect analysis.
• A large-scale, randomized controlled trial is recommended to definitively establish CCB efficacy.